Bausch Health Prevails in U.S. District Court Case

Bausch Health Companies Inc., along with Salix Pharmaceuticals, announced a favorable ruling from the U.S. District Court for the District of Columbia. The court denied Norwich Pharmaceuticals' motion against the FDA, which sought to challenge the FDA's tentative approval of Norwich's application for XIFAXAN® (rifaximin) 550 mg and claim forfeiture by Teva Pharmaceuticals of their exclusivity period.

Norwich aimed to market their product before June 2028, contingent upon Teva's potential launch in January 2028. However, the court's decision supported the FDA, Salix, and Teva, effectively closing the case.

Bausch Health CEO Thomas J. Appio expressed satisfaction with the outcome, affirming their commitment to patient access to XIFAXAN. The company is set to release its first-quarter financial results on April 30, 2025.